Showing results (1341-1350 of 1,611) with videos related to

Sort By:
Pageof 162
JAMA Oncology|February 15, 2017
Effect of Radiotherapy on Painful Bone Metastases: A Secondary Analysis of the NCIC Clinical Trials Group Symptom Control Trial SC.23Rachel McDonald, Keyue Ding, Michael Brundage, et al.
JAMA Oncology|November 18, 2021
Association of Treatment Modality, Functional Outcomes, and Baseline Characteristics With Treatment-Related Regret Among Men With Localized Prostate CancerChristopher J D Wallis, Zhiguo Zhao, Li-Ching Huang, et al.
JAMA Oncology|November 18, 2021
Treatment Selection in First-line Metastatic Renal Cell Carcinoma-The Contemporary Treatment Paradigm in the Age of Combination Therapy: A ReviewVishal Navani, Daniel Y C Heng
JAMA Oncology|August 23, 2019
Multiomics Prediction of Response Rates to Therapies to Inhibit Programmed Cell Death 1 and Programmed Cell Death 1 Ligand 1Joo Sang Lee, Eytan Ruppin
JAMA Oncology|August 2, 2019
Assessment of Molecular Relapse Detection in Early-Stage Breast CancerIsaac Garcia-Murillas, Neha Chopra, Iñaki Comino-Méndez, et al.
JAMA Oncology|September 15, 2022
Expanded Parameters in Active Surveillance for Low-risk Papillary Thyroid Carcinoma: A Nonrandomized Controlled TrialAllen S Ho, Sungjin Kim, Cynthia Zalt, et al.
JAMA Oncology|September 15, 2022
An Overview of Clinical Development of Agents for Metastatic or Advanced Breast Cancer Without ERBB2 Amplification (HER2-Low)Aleix Prat, Aditya Bardia, Giuseppe Curigliano, et al.
JAMA Oncology|November 4, 2021
Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer: A Multicenter International Cohort StudyCaroline A Nebhan, Alessio Cortellini, Weijie Ma, et al.
JAMA Oncology|January 20, 2022
Evaluation of Substantial Reduction in Elective Radiotherapy Dose and Field in Patients With Human Papillomavirus-Associated Oropharyngeal Carcinoma Treated With Definitive ChemoradiotherapyC Jillian Tsai, Sean M McBride, Nadeem Riaz, et al.
JAMA Oncology|August 25, 2022
Association of PD-L1 Expression and Other Variables With Benefit From Immune Checkpoint Inhibition in Advanced Gastroesophageal Cancer: Systematic Review and Meta-analysis of 17 Phase 3 Randomized Clinical TrialsHarry H Yoon, Zhaohui Jin, Oudom Kour, et al.
Pageof 162